Spin-outs

Spin-outs

The Institute has a culture and history of scaling technologies, some of these capabilities have become spin-outs that present an important opportunity to benefit the healthcare sector.

Go back to Case Studies

Congenica Ltd

congenica_logo.png

Congenica develops products and services for the interpretation of genomes, with a focus on rare diseases. Congenica's first product, SAPIENTIA TM is built upon world leading technology developed by the Wellcome Trust Sanger Institute, including the work of Dr Richard Durbin and Dr Matthew Hurles scientific leaders respectively of the 1000 genomes project and of the ‘Deciphering Developmental Disorders’ (DDD) study, the world’s largest, nationwide genome-wide rare disease sequencing programme. More

Kymab

Kymab spin-off logo

Kymab was founded by Professor Allan Bradley, FRS, in 2010, based on developments in his laboratory at the Wellcome Trust Sanger Institute. Raising $30m of equity financing in 2010 from the Wellcome Trust Investment Division has enabled the development of the KymouseTM platform and the creation of a portfolio of therapeutic assets. The KymouseTM platform encompasses the entire diversity of the B lymphocyte component of the human immune system. Kymab has around 100 staff and is headquartered on the Babraham Research Campus, three miles from Cambridge Biomedical Campus, the MRC Laboratory of Molecular Biology and Addenbrooke’s Teaching Hospital. More

VHsquared Ltd

vhsquared logo

VHsquared Ltd. develops oral biologics for immuno-inflammatory targets in the gastro intestinal tract. The company identifies, screens, selects, and engineers Vorabodies, a transformational therapy for the treatment of inflammatory bowel disease. It uses its Vorabody platform to generate potent protease resistant domain antibodies for oral administration. The company was incorporated in 2010 and is based in Cambridge, United Kingdom. More

Microbiotica

microbiotica logo_artwork.jpg

Microbiotica, is the latest spin-out from the Sanger Institute received its funding from Cambridge Innovation Capital (CIC) and IP Group to use the latest discoveries in the characterisation of our bacteria and their role in health and disease to develop bacteriotherapy - a radical way to treat disease based on using the bacteria themselves. More